LeadingBiotech: South CEO is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Brian Gallagher
Partner at Abingworth

Profile

Brian M. Gallagher, Jr., Ph.D. is a Partner at Abingworth in Boston which he joined in 2018 and where he is focused on building innovative therapeutic and life science companies. Dr. Gallagher has over 20 years of investing, business development, operational and R&D experience in both biotechnology and large pharma companies. He currently is on the board of Translate Bio (NASDAQ: TBIO). He previously led investments in and was on the boards of Aileron Therapeutics (NASDAQ: ALRN), CalciMedica, Constellation Pharmaceuticals (NASDAQ: CNST), Dicerna Pharmaceuticals (NASDAQ: DRNA), Navitor Pharmaceuticals, Nimbus Therapeutics, Princeps Therapeutics, River Vision (acquired by Horizon Pharma), and SpringLeaf Therapeutics.

Dr. Gallagher joined Abingworth from SR One Ltd where he was a Partner and established the SR One Boston office in 2010. Prior to SR One he was with Sirtris Pharmaceuticals, where he was responsible for corporate development, operations and post-merger integration following the $720M acquisition of Sirtris by GlaxoSmithKline in 2008. Prior to Sirtris, Dr. Gallagher was with Alantos Pharmaceuticals, where he played key roles in the R&D and business development activities and led many aspects of the post-merger integration following the $300M acquisition of Alantos by Amgen in 2007. He began his career in R&D at the Japanese pharma Eisai, where he was a group leader for multiple programs in the oncology and inflammation/immunology therapeutic areas.

Dr. Gallagher is an inventor on over 25 patents and patent applications and is the senior author of a number of scientific publications. He currently serves on the Investment Advisory Board for University of Michigan Monroe-Brown Biomedical Seed Fund, and the Industry Advisory Boards for NYU Medical School and the National Brain Tumor Society. He has also served as a mentor for NVCA Corporate VC Mentorship Program and MassBio’s MassCONNECT, and as a peer reviewer/editorial board member for numerous journals and research funding authorities. Dr. Gallagher received his MS and PhD degrees in organic chemistry from the University of Michigan and his BS in chemistry from the University of Massachusetts, where he was a Shapiro scholar.